Literature DB >> 2537870

Synthesis and regulation of C1 inhibitor in human skin fibroblasts.

Y Katz1, R C Strunk.   

Abstract

Proteins of the C1 complex, C1q, C1r, and C1s, of the classical pathway of complement activation are known to be synthesized in human skin fibroblasts. Using metabolic labeling with [35S]methionine, immunoprecipitation, and SDS-PAGE, we demonstrate that human skin fibroblasts synthesize and secrete C1 inhibitor with an apparent molecular mass of 78 kDa in the cell lysate and 102 kDa in the extracellular medium. This C1 inhibitor had the capacity to bind activated C1s. Fibroblasts synthesized 30- to 50-fold more C1 inhibitor than was synthesized in monocytes. As previously reported, fibroblasts also synthesized C1r and C1s. IFN-gamma, IFN-beta 1, and TNF had significant, but distinct, effects on synthesis of C1 inhibitor, C1r, and C1s. Incubation of the cells with IFN-gamma, 1000 U/ml, for 24 h induced increases in the synthesis of C1 inhibitor, C1r, and C1s by 4.2-, 1.9- and 1.6-fold, respectively. IFN-beta 1 had effects similar to IFN-gamma, although smaller in magnitude. TNF, 12.5 ng/ml, induced increases in the synthesis of C1 inhibitor, C1r, and C1s by 1.5-, 1.4- and 2.6-fold. IL-1, IFN-beta 2 (IL-6), and LPS did not affect synthesis of C1 inhibitor, C1r, or C1s. Fibroblasts are present in large amounts in most tissues. Synthesis of C1 inhibitor, C1r, and C1s by these cells could provide a source of these important proteins in body tissues. In addition, fibroblasts should be a good model for the in vitro study of genetic diseases involving the synthesis of these proteins.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2537870

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Dysfunctional C1 inhibitor Ta: deletion of Lys-251 results in acquisition of an N-glycosylation site.

Authors:  R B Parad; J Kramer; R C Strunk; F S Rosen; A E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

2.  Complement C1s activation in degenerating articular cartilage of rheumatoid arthritis patients: immunohistochemical studies with an active form specific antibody.

Authors:  K Nakagawa; H Sakiyama; T Tsuchida; K Yamaguchi; T Toyoguchi; R Masuda; H Moriya
Journal:  Ann Rheum Dis       Date:  1999-03       Impact factor: 19.103

Review 3.  Complement System and Alarmin HMGB1 Crosstalk: For Better or Worse.

Authors:  Christine Gaboriaud; Marie Lorvellec; Véronique Rossi; Chantal Dumestre-Pérard; Nicole M Thielens
Journal:  Front Immunol       Date:  2022-04-28       Impact factor: 8.786

4.  Synthesis of C1 inhibitor in fibroblasts from patients with type I and type II hereditary angioneurotic edema.

Authors:  J Kramer; Y Katz; F S Rosen; A E Davis; R C Strunk
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

5.  Synthesis of the third component of complement (C3) by human gastric cancer-derived cell lines.

Authors:  E Kitano; H Kitamura
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

6.  Effect of interferon-gamma on complement gene expression in different cell types.

Authors:  D F Lappin; D Guc; A Hill; T McShane; K Whaley
Journal:  Biochem J       Date:  1992-01-15       Impact factor: 3.857

7.  IL-13 results in differential regulation of the complement proteins C3 and factor B in tumour necrosis factor (TNF)-stimulated fibroblasts.

Authors:  Y Katz; D Stav; J Barr; J H Passwell
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

8.  C1 esterase inhibitor gene expression in rat Kupffer cells, peritoneal macrophages and blood monocytes: modulation by interferon gamma.

Authors:  T Armbrust; S Schwögler; G Zöhrens; G Ramadori
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.